Concord Biotech Invests in Palvella Therapeutics for Rare Skin Disease Drug
December 12, 2024 14:28
Concord Biotech invests USD 10 lakh in Palvella Therapeutics to manufacture and commercialize 'Qtorin', a drug for rare genetic skin diseases. The investment will strengthen their partnership and...